Cell-Free Assembly of Organized Collagen Arrays
有组织的胶原阵列的无细胞组装
基本信息
- 批准号:7241873
- 负责人:
- 金额:$ 22.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:AchievementAddressAffectAmericanAneurysmArchitectureBasic ScienceBiocompatible MaterialsBirthCell surfaceCell-Free SystemCellsCicatrixClinicalCollagenCollagen FibrilComplexConditionConnective TissueCorneaCorneal StromaDegenerative DisorderDegenerative polyarthritisDevelopmentDiseaseEconomicsEmbryonic DevelopmentEngineeringExerciseExtracellular MatrixFibrillar CollagenFibroblastsHereditary DiseaseImageIn VitroIndividualInvestigationKeratoplastyKineticsLaboratoriesLifeLigamentsMechanicsMethodsMyopathyOsteogenesis ImperfectaOsteoporosisPrincipal InvestigatorProcessProductionPropertyProteinsResearchSilkSyndromeSystemTendon structureTestingTimeTissue EngineeringTissuesTranslatingTransplanted tissueUncertaintyUrsidae FamilyWeight-Bearing stateWorkWound Healinganalogbasecostfibrillogenesisimplantationimprovedin vitro Modelin vivomethod developmentmimeticsmodel developmentmonomernanoscalenovelprogramsreconstructionrepairedscaffoldsuccesstime use
项目摘要
DESCRIPTION (provided by applicant): Collagen is the principle load-bearing molecule and most abundant protein in the body. Collagen degenerative diseases include osteoarthritis (affecting 10% of Americans 60 years or older), osteoporosis (affecting 28 million Americans), arterial aneurysms and intervetebral disc disease. There are 50,000 corneal transplants and 200,000 primary ACL reconstructions performed in the US each year demonstrating the need for suitable, mechanically strong graft material. Collagen-related genetic disorders are equally devastating; examples include osteogenesis imperfecta (affecting 27,000 people in the US), many chondrodysplasias (1 in 4,000 births), and various syndromes (i.e. Ehlers-Danlos, Alport and Bethlem myopathy). The economic impact of these diseases is enormous; osteoarthritis alone costs the US economy more than $60 billion annually. In spite of this, little is known about the mechanisms that govern collagen assembly in vivo which has limited the ability of tissue engineers to reproduce collagenous load-bearing tissue in the laboratory. Instead, tissue engineering utilizes cell-seeded, degradable synthetic or self-assembled, collagenous scaffolds which require resorption and remodeling to be functional. Resorption and remodeling of scaffolds closely resembles in vivo scar remodeling or wound healing which can take years to complete, even under ideal conditions. Consequently, no functional load-bearing tissue-engineered equivalents have met with clinical success. A method to construct mechanically strong, collagenous matrix should improve the chances of producing functional connective tissue equivalents. Collagen matrices must be highly ordered and highly concentrated to possess adequate strength. It is thus necessary to organize collagen at the nanoscale in a manner similar to embryonic development where fibroblast cells exercise exquisite control over the fibrillogenesis of collagen. Though little is known about the detailed mechanics of this process there are two competing hypotheses which suggest that collagen is either: a) synthesized, assembled and organized by individual cells via cell-surface fibropositors or b) secreted in monomer form and then assembled into an organized matrix via cholesteric effects. In the proposed work, we will observe organized matrix assembly using time-lapse live dynamic differential interference contrast imaging of individual cells in a novel in vitro model of corneal stromal ECM development. We will then produce organized collagenous matrices de novo by mimicking the development mechanism in one of two in vitro cell-free systems currently under development in our laboratory. If successful, the proposed investigation will answer a critical basic science question regarding development and then translate those results into a process capable of producing load-bearing collagenous tissue equivalents.
描述(由申请人提供):胶原蛋白是主要的承重分子,也是体内最丰富的蛋白质。胶原变性疾病包括骨关节炎(影响10%的60岁或以上的美国人),骨质疏松症(影响2800万美国人),动脉瘤和椎间盘疾病。美国每年进行50,000例角膜移植和200,000例初次ACL重建,证明需要合适的机械强度高的移植材料。胶原蛋白相关的遗传疾病同样具有破坏性;例子包括成骨不全(在美国影响27,000人),许多软骨发育不良(4,000名新生儿中有1名)和各种综合征(即Ehlers-Danlos,Alport和Bethlem肌病)。这些疾病的经济影响是巨大的;仅骨关节炎一项,每年就给美国经济造成600多亿美元的损失。尽管如此,很少有人知道的机制,在体内的胶原蛋白组装,限制了组织工程师在实验室中复制胶原承重组织的能力。相反,组织工程利用细胞接种的、可降解的合成或自组装的胶原支架,其需要再吸收和重塑才能发挥功能。支架的再吸收和重塑与体内瘢痕重塑或伤口愈合非常相似,即使在理想条件下也需要数年才能完成。因此,没有功能性承重组织工程等同物获得临床成功。构建机械强度强的胶原基质的方法应提高产生功能性结缔组织等同物的机会。胶原基质必须高度有序和高度浓缩以具有足够的强度。因此,有必要以类似于胚胎发育的方式在纳米级组织胶原蛋白,其中成纤维细胞对胶原蛋白的原纤维形成进行精密控制。尽管对这一过程的详细机制知之甚少,但有两种相互竞争的假设表明胶原蛋白是:a)由单个细胞通过细胞表面纤维定位器合成、组装和组织化的,或B)以单体形式分泌,然后通过细胞增殖效应组装成有组织的基质。在拟议的工作中,我们将观察有组织的矩阵组装使用延时活动态差分干涉对比成像的单个细胞在一个新的体外模型的角膜基质ECM的发展。然后,我们将通过模仿我们实验室目前正在开发的两种体外无细胞系统之一的发育机制,从头产生有组织的胶原基质。如果成功,拟议的研究将回答一个关于发育的关键基础科学问题,然后将这些结果转化为能够产生承重胶原组织等同物的过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey W Ruberti其他文献
Jeffrey W Ruberti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey W Ruberti', 18)}}的其他基金
Mechanical Causation of Corneal Stromal Matrix Synthesis and Fibrosis
角膜基质基质合成和纤维化的机械原因
- 批准号:
10659976 - 财政年份:2023
- 资助金额:
$ 22.41万 - 项目类别:
Cell-Free Assembly of Organized Collagen Arrays
有组织的胶原阵列的无细胞组装
- 批准号:
7359669 - 财政年份:2007
- 资助金额:
$ 22.41万 - 项目类别:
Investigation of Collagen as a Smart Engineering Material
胶原蛋白作为智能工程材料的研究
- 批准号:
7230087 - 财政年份:2006
- 资助金额:
$ 22.41万 - 项目类别:
Investigation of Collagen as a Smart Engineering Material
胶原蛋白作为智能工程材料的研究
- 批准号:
7077109 - 财政年份:2006
- 资助金额:
$ 22.41万 - 项目类别:
Mechanobiology of Matrix Production by Corneal Fibroblasts
角膜成纤维细胞基质产生的力学生物学
- 批准号:
8387865 - 财政年份:2005
- 资助金额:
$ 22.41万 - 项目类别:
Mechanobiology of Matrix Production by Corneal Fibroblasts
角膜成纤维细胞基质产生的力学生物学
- 批准号:
8539623 - 财政年份:2005
- 资助金额:
$ 22.41万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.41万 - 项目类别:
Research Grant














{{item.name}}会员




